Unlike general weight loss drugs, it doesn't work primarily by suppressing appetite
Third, the 2-4% weight loss difference (if confirmed) may be statistically significant in studies but have little practical meaning for specific individuals
J Clin Endocrinol Metab 104(8):30773087
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
Either way, you deserve to ask the question
In order for you to maintain the effect of our appetite suppressant therapy in the long term, it is necessary that you change your previous behavior